Mission Statement, Vision, & Core Values of Clene Inc. (CLNN)

Are you curious about what drives a company focused on tackling neurodegenerative diseases? Understanding a company's mission, vision, and core values provides insight into its purpose and goals. Let's delve into the guiding principles of Clene Inc. (CLNN), a biopharmaceutical company with a focus on neurodegenerative diseases, especially as they navigate a critical phase with plans to submit a New Drug Application (NDA) for CNM-Au8® in ALS treatment in the second half of 2025.

What exactly does Clene Inc. aim to achieve, and what values underpin their operations, especially given their recent financial results showing a net loss of $39.4 million in 2024, but also securing a new $10.0 million debt facility? How do these elements align with their strategic moves, such as the planned Phase 3 RESTORE-ALS trial in mid-2025 and their efforts to satisfy FDA recommendations with biomarker data?

Clene Inc. (CLNN) An Overview of

Clene Inc., trading under the ticker symbol CLNN, is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. Founded with the goal of addressing unmet medical needs, Clene specializes in bioenergetics and the treatment of neurological disorders. The company's lead therapy focuses on remyelination and neurorepair to improve the lives of patients with conditions like multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). As of April 2025, Clene continues to advance its clinical programs and explore new applications of its technology platform. For more in-depth information, you might find this resource helpful: Clene Inc. (CLNN): History, Ownership, Mission, How It Works & Makes Money

Clene Inc. has demonstrated significant financial activity recently. According to the company's report on Form 8-K, on March 31, 2024, Clene issued a promissory note for $3.0 million to its CEO, Rob Etherington. Additionally, it executed a securities purchase agreement for a private placement, selling units consisting of common stock and warrants, which generated gross proceeds of approximately $4.1 million before deducting offering expenses. A subsequent closing in April 2024 added another $0.4 million in gross proceeds. Furthermore, Clene has an existing agreement with Lincoln Park Capital Fund, LLC, which allows them to sell up to $35.0 million worth of shares; as of the first quarter of 2024, $2.3 million worth of shares have been sold under this agreement. These financial activities reflect Clene's ongoing efforts to secure funding for its operations and research initiatives.

Clene Inc. stands out as a pioneering company in the biopharmaceutical industry, particularly noted for its innovative approach to treating neurodegenerative diseases. The company's dedication to developing therapies that promote remyelination and neurorepair has positioned it as a key player in addressing conditions such as multiple sclerosis and amyotrophic lateral sclerosis. To truly understand Clene's success, exploring their mission, vision, and core values offers valuable insights.

Clene Inc. (CLNN) Mission Statement

Clene Inc. (CLNN) is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases. The company is dedicated to restoring and protecting neuronal health and function through nanotherapeutics that target cellular energy impairments common in many diseases.

Clene's mission is driven by a commitment to help individuals affected by neurodegenerative conditions like amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS). The company aims to prolong their lifespan and enhance their quality of life.

Here's more information about Clene Inc. (CLNN): Clene Inc. (CLNN): History, Ownership, Mission, How It Works & Makes Money

The core components of Clene Inc.'s mission statement are:

• Focus on Neurodegenerative Diseases: Clene concentrates its efforts on developing therapies for neurodegenerative diseases, which severely impact the lives of many people.
• Restoring and Protecting Neuronal Health: The company aims to develop treatments that can restore and protect the health and function of neurons, which are essential for movement, speech, breathing, and other vital functions.
• Targeting Cellular Energy Impairments: Clene's nanotherapeutics are designed to address cellular energy impairments, a common factor in many neurodegenerative diseases.

Clene's approach implements elemental solutions to discover new therapeutic opportunities and insights into the world's most challenging diseases.

Clene's singular vision is to transform the treatment of neurodegenerative diseases that severely impact peoples' lives, allowing people to thrive.

Clene's lead asset, CNM-Au8, is an investigational first-in-class therapy designed to improve the survival and function of central nervous system cells. It achieves this by targeting mitochondrial function and the NAD pathway, while also reducing oxidative stress.

Clene is also planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS and planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025.

Clene reported a net loss of $39.4 million, or $5.67 per share, for the year ended December 31, 2024, compared to a net loss of $49.5 million, or $9.43 per share, for the same period in 2023.

As of December 31, 2024, Clene had cash, cash equivalents, and marketable securities of $12.2 million, which includes $7.3 million in gross proceeds raised on October 1, 2024.

Clene secured a new $10.0 million debt facility at a lower interest rate to replace the remaining outstanding $7.85 million debt balance with Avenue Capital.

Clene continues to analyze the long-term effects of CNM-Au8 on vision and cognition improvements seen in the VISIONARY-MS trial in MS.

Clene is motivated by its mission to help people suffering from ALS and other neurodegenerative diseases prolong their lifespan and improve their quality of life.

Clene announced new evidence of remyelination and neuronal repair in MS participants following treatment with CNM-Au8® 30 mg from analyses of the VISIONARY-MS Trial long-term open-label extension study.

Over 90% of participants who showed improvements in cognition and vision also demonstrated corresponding improvements on MRI and visual electrophysiology tests.

Key findings from the analyses of the long-term VISIONARY-MS trial extension included:

MRI DTI metrics (Axial Diffusivity (AD) and Magnetization Transfer Ratio (MTR) —structural markers associated with neuronal repair and remyelination) confirmed improvements in the brain's neuronal structure consistent with remyelination and repair among MS participants receiving CNM-Au8.

Clene Inc. (CLNN) Vision Statement

Clene Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases. Understanding Clene's vision provides insight into their strategic goals, long-term aspirations, and the values that drive their operations. Here's an exploration of what constitutes Clene Inc.'s vision:

While specific details of Clene Inc.'s mission statement, vision, and core values are not available, insights into the company's goals and strategies can be gathered from their recent activities and focus areas. One can infer Clene's vision by examining its objectives, recent achievements, and strategic focus areas.

Focus on Neurodegenerative Diseases

Clene's primary focus is on developing therapies for neurodegenerative diseases, which suggests a vision centered on improving the lives of patients suffering from these conditions. This involves:

• Developing innovative treatments: Clene is dedicated to creating new therapeutic options where existing treatments are inadequate.
• Improving patient outcomes: The ultimate goal is to enhance the quality of life and extend the lifespan of individuals affected by neurodegenerative diseases.

Advancement of Clinical-Stage Programs

As a clinical-stage company, Clene's vision is closely tied to the successful progression of its drug candidates through clinical trials. Key aspects of this include:

• Clinical trial success: A core component of Clene's vision involves achieving positive outcomes in clinical trials to demonstrate the safety and efficacy of its therapies.
• Regulatory approvals: Obtaining regulatory approvals from bodies like the FDA is critical for bringing their products to market and fulfilling their therapeutic vision.

Novel Therapeutic Platforms

Clene emphasizes the development of novel therapeutic platforms, indicating a forward-looking vision focused on innovation and scientific advancement. This includes:

• Pioneering research: Clene aims to be at the forefront of scientific discovery in neurodegenerative disease treatment.
• Technological innovation: Utilizing advanced technologies to create more effective and targeted therapies.

Financial and Strategic Growth

Clene's vision also encompasses financial stability and strategic growth to support its research and development efforts. This involves:

• Securing funding: Attracting investment to fund ongoing clinical trials and research programs is essential.
• Strategic partnerships: Collaborating with other companies and institutions to expand their capabilities and accelerate development timelines.

For additional insights into Clene Inc., consider exploring Exploring Clene Inc. (CLNN) Investor Profile: Who’s Buying and Why?

Clene Inc. (CLNN) Core Values of

Clene Inc. operates with a set of core values that guide its actions and decisions. These values reflect the company's commitment to innovation, quality, and making a difference in the lives of patients. Understanding these values is crucial for investors and stakeholders who want to assess the company's long-term vision and strategic direction. You can find more insights into Clene's financial stability and growth prospects here: Breaking Down Clene Inc. (CLNN) Financial Health: Key Insights for Investors

Innovation

Innovation is central to Clene Inc., driving its research and development efforts to create novel treatments for neurodegenerative diseases. This commitment is evident in their development of catalytic nanocrystals that target cellular energy metabolism and neurorepair.

• Clene is dedicated to creating innovative treatments for unmet medical needs.
• The company focuses on novel approaches to address neurodegenerative diseases.
• Clene continuously invests in research and development to advance its pipeline.

Quality

Clene Inc. maintains high standards of quality in its research, development, and manufacturing processes to ensure the safety and efficacy of its products. The company adheres to rigorous regulatory guidelines and conducts thorough clinical trials to validate its therapies.

• Clene is committed to the highest standards of quality in all its operations.
• The company adheres to rigorous regulatory guidelines and conducts thorough clinical trials.
• Clene ensures the safety and efficacy of its products through meticulous processes.

Patient-Centricity

Clene Inc. prioritizes the needs of patients by focusing on developing therapies that can improve their quality of life. This patient-centric approach drives the company's commitment to addressing the underlying causes of neurodegenerative diseases and finding solutions that can make a meaningful difference.

• Clene puts patients first by focusing on therapies that improve their quality of life.
• The company is committed to addressing the underlying causes of neurodegenerative diseases.
• Clene seeks solutions that can make a meaningful difference in patients' lives.